Inactive Instrument

Decibel Therapeutics, Inc.

Equities

DBTX

US24343R1068

Biotechnology & Medical Research

Decibel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 14, 2023 at 04:02 pm

Decibel Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 63.005 million compared to USD 54.132 million a year ago. Basic loss per share from continuing operations was USD 2.52 compared to USD 2.49 a year ago.

Diluted loss per share from continuing operations was USD 2.52 compared to USD 2.49 a year ago.

Latest news about Decibel Therapeutics, Inc.

Regeneron Pharmaceuticals Completes Acquisition of Decibel Therapeutics	23-09-25	MT
Decibel Therapeutics, Inc. Announces Board Changes	23-09-25	CI
Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from NASDAQ Composite Index	23-09-25	CI
Decibel Therapeutics, Inc.(NasdaqGS:DBTX) dropped from S&P TMI Index	23-09-25	CI
Regeneron Pharmaceuticals, Inc. acquired remaining 91.65% stake in Decibel Therapeutics, Inc. from a group of shareholders.	23-09-24	CI
Decibel Therapeutics' Gene Therapy Candidate Granted US FDA's Fast-Track Designation	23-08-25	MT
Decibel Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation for DB-OTO	23-08-25	CI
Decibel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
North American Morning Briefing : Stock Futures -2-	23-08-11	DJ
Global markets live: Allianz, Generali, Sony, Disney, Alibaba...	23-08-10
Baird Downgrades Decibel Therapeutics to Neutral From Outperform, Adjusts Price Target to $5.25 From $21	23-08-10	MT
North American Morning Briefing : Attention Turns -2-	23-08-10	DJ
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	23-08-09	MT
Sector Update: Health Care	23-08-09	MT
Top Midday Gainers	23-08-09	MT
Regeneron Pharmaceuticals Signs Agreement to Acquire Decibel Therapeutics at $4 per Share	23-08-09	MT
HC Wainwright Downgrades Decibel Therapeutics to Neutral From Buy	23-08-09	MT
Decibel Therapeutics Shares Surge on Regeneron Acquisition	23-08-09	DJ
Regeneron To Acquire Decibel Therapeutics	23-08-09	DJ
Regeneron Pharmaceuticals, Inc. entered into a definitive agreement to acquire remaining unknown majority stake in Decibel Therapeutics, Inc..	23-08-08	CI
Decibel Therapeutics, Inc.(NasdaqGS:DBTX) added to Russell 3000E Growth Index	23-06-23	CI
Decibel Therapeutics, Inc.(NasdaqGS:DBTX) added to Russell Microcap Growth Index	23-06-23	CI
Decibel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Decibel Therapeutics Says Spanish Regulators Approved Its Application for Clinical Trial of Gene Therapy	23-05-12	MT
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to Initiate Clinical Development of Lead Gene Therapy Candidate Db-OTO	23-05-12	CI

Chart Decibel Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorder. It is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company's pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+28.99%	49.18B
IQVIA HOLDINGS INC.	+0.82%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.34%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.63%	18.71B
BIO-TECHNE CORPORATION	+8.06%	13.26B
MEDPACE HOLDINGS, INC.	+32.17%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.38%	11.99B

Other Biotechnology & Medical Research